Report : North America Metastatic Cancer Drugs Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous and Intramuscular), Drug Class (HER2 Inhibitors, Immune Checkpoint Inhibitors, PARP Inhibitors, Kinase Inhibitors, and Others), Product (Branded, Generics, and Biosimilars), and End User (Hospital, Specialty Clinic, and Others)
PARP Inhibitors segment has the Largest Share of Drug Class in the North America Metastatic Cancer Drug Market during 2019–2028
According to our latest study on “North America Metastatic Cancer Drug Market Forecast to 2028 – COVID-19 Impact and Analysis – by Cancer Type, Route of Administration, Drug Class, Product, End User” the market is projected to reach US$ 27,989.14 million by 2028 from US$ 21,414.73 million in 2021; it is expected to grow at a CAGR of 3.9% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high prevalence of cancer and government initiatives to support developments in cancer treatment. However, complex technological process and high initial investment hampers the market growth.
Based on drug class, has been segmented into HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others. In 2021, the PARP inhibitors segment accounted for the largest share of the market; it is further expected to continue its dominance over the forecast period. This class of drugs are used to prevent the cell from damage repair and dies. Thus, it helps in the slowing down the growth of cancer cells and prevents from spreading to other body parts. On the other hand, HER2 inhibitors drug class segment is expected to register the highest CAGR in the metastatic cancer drugs market during 2021–2028.
AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., Novartis AG, Astrazeneca, Eli Lilly and Company, MERCK KGaA, Pfizer Inc. (Arena Pharmaceutical GmbH), Johnson and Johnson Services, Inc., are among the leading companies in the North America metastatic cancer drug market .The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
The market for North America metastatic cancer drugs market is segmented into cancer type, route of administration, drug class, product, and end user. Based on cancer type, the market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the North America metastatic cancer drugs market is segmented into intravenous, and intramuscular. Based on drug class, the market is segmented into HER2 inhibitors, immune checkpoint inhibitors, parp inhibitors, kinase inhibitors, and others. Based on product, the market is segmented into branded, generics and biosimilars. Based on end user, the North America metastatic cancer drugs market is segmented into hospital, specialty clinic, and others. By Country, the North America metastatic cancer drugs market is segmented into US, Mexico and Canada.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: firstname.lastname@example.org